Nanobiotix, Janssen Pharmaceutica Reach Global Licensing and Commercialization Deal
Agreement to focus on the treatment of patients with advanced head and neck cancer.
Nanobiotix, a late-clinical stage biotechnology company, has reached a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, for the potential of NBTXR3 across solid tumor indications. The treatment is currently being evaluated in patients with advanced head and neck cancer.
As per the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3. Despite having an exclusive license, the deal will not be attributed to territories previously given to Nanobiotix partner LianBio.
“We expect this agreement, and the collaboration it enables, to further drive the expansion of NBTXR3 development and accelerate the realization of its promise for patients in need,” said Bart van Rhijn, chief financial officer, Nanobiotix. “We look forward to maximizing the value of NBTXR3 for our global stakeholders.”
Reference: NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3. Nanobiotix. July 10, 2023. Accessed July 11, 2023. https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-license-agreement-worldwide-co-development
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
